These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12064785)

  • 1. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.
    Goberman A; Coelho C; Robb M
    J Commun Disord; 2002; 35(3):217-39. PubMed ID: 12064785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa].
    Azevedo LL; Cardoso F; Reis C
    Arq Neuropsiquiatr; 2003 Dec; 61(4):995-8. PubMed ID: 14762605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
    Goberman AM
    Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of levodopa on vocal function in Parkinson's disease.
    Sanabria J; Ruiz PG; Gutierrez R; Marquez F; Escobar P; Gentil M; Cenjor C
    Clin Neuropharmacol; 2001; 24(2):99-102. PubMed ID: 11307045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease.
    Goberman AM; Blomgren M
    J Voice; 2008 Mar; 22(2):178-91. PubMed ID: 16950600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For better or worse: The effect of levodopa on speech in Parkinson's disease.
    Ho AK; Bradshaw JL; Iansek R
    Mov Disord; 2008 Mar; 23(4):574-80. PubMed ID: 18163453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.
    Goberman AM; Blomgren M
    J Fluency Disord; 2003; 28(1):55-70. PubMed ID: 12706913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].
    Ghio A; Robert D; Grigoli C; Mas M; Delooze C; Mercier C; Viallet F
    Rev Laryngol Otol Rhinol (Bord); 2014; 135(2):63-70. PubMed ID: 26521344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
    De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
    Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glottographic measures before and after levodopa treatment in Parkinson's disease.
    Jiang J; Lin E; Wang J; Hanson DG
    Laryngoscope; 1999 Aug; 109(8):1287-94. PubMed ID: 10443835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prosody and levodopa in Parkinson's disease.
    Azevedo LL; Reis CA; Souza IS; Cardoso FE
    Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
    Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
    Behav Brain Res; 2012 Apr; 230(1):116-24. PubMed ID: 22343069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
    Lechien JR; Blecic S; Ghosez Y; Huet K; Harmegnies B; Saussez S
    J Voice; 2019 Sep; 33(5):716-720. PubMed ID: 29724466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease.
    Gallena S; Smith PJ; Zeffiro T; Ludlow CL
    J Speech Lang Hear Res; 2001 Dec; 44(6):1284-99. PubMed ID: 11776365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speech motor control in Parkinson's disease: a comparison between a clinical assessment protocol and a quantitative analysis of mandibular movements.
    Svensson P; Henningson C; Karlsson S
    Folia Phoniatr (Basel); 1993; 45(4):157-64. PubMed ID: 8406265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on parkinsonian voice using perturbation, nonlinear dynamic, and perceptual analysis.
    Zhou XP; Lee VS; Wang EQ; Jiang JJ
    Folia Phoniatr Logop; 2009; 61(4):189-99. PubMed ID: 19590218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
    Pinho P; Monteiro L; Soares MFP; Tourinho L; Melo A; Nóbrega AC
    Codas; 2018 Oct; 30(5):e20170200. PubMed ID: 30304100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.